What is it?
What is Retatrutide?
Retatrutide is an investigational peptide-based triple receptor agonist. A single molecule activates receptors for GIP, GLP-1 and glucagon, making it conceptually distinct from Semaglutide and Tirzepatide.
Peptide Profile
Retatrutide
Retatrutide is an investigational peptide-based triple receptor agonist. A single molecule activates receptors for GIP, GLP-1 and glucagon, making it conceptually distinct from Semaglutide and Tirzepatide.
GIP + GLP-1 + GlucagonInvestigationalPhase 2 + 3NEJMLilly
Receptor profile
GIP + GLP-1 + Glucagon
Its receptor profile includes three targets: the GIP receptor, GLP-1 receptor and glucagon receptor. The term “triple agonist” describes this combined profile more accurately than informal labels such as “GLP-3”.
Scientific status
Context
Retatrutide remains in clinical development. Lilly reported Phase 3 results during 2026; as of the current status it has not been approved by a regulatory authority. The status on this page is therefore dated October 2026.
Peptide analytics
Documentation instead of generic claims.
For investigational peptides as well, identity, purity and other quality characteristics should never be claimed generically. Such statements belong to a specific batch and to the analytical documentation actually available.
References & studies
Sources directly related to this peptide.
Official references and selected peer-reviewed studies. Study links are provided for scientific context and are not administration guidance.
Current development status
Eli Lilly · What to know about retatrutide
Lilly · zuletzt aktualisiert 09/2026Current sponsor information on investigational status and GIP/GLP-1/glucagon triple agonism.
Open source ↗Phase 2 studyTriple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff et al. · N Engl J Med · 2023 · PMID 37366315Peer-reviewed randomized phase 2 trial investigating retatrutide.
Open source ↗Phase 3 studyTRIUMPH-1 · Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Jastreboff et al. · N Engl J Med · 2026 · DOI 10.1056/NEJMoa2604169Peer-reviewed randomized phase 3 trial published online September 29, 2026.
Open source ↗